Alzamend Neuro cuts preferred stock financing to $10 million from $25 million in amended agreement
ALZN•Alzamend Neuro amended its Series D convertible preferred stock financing with affiliate Ault Lending, reducing it to $10 million from $25 million. The revised agreement requires a $2.5 million second tranche and sets conversion pricing at 80% of the lowest closing bid over five preceding trading days, subject to a $0.2668 floor and $2 cap.
1. Amended financing terms
Alzamend Neuro amended the financing agreement with affiliate Ault Lending on November 10, 2026, reducing the total from $25 million to $10 million. A $7.5 million initial purchase was made on July 31, 2026, and the revised agreement requires a $2.5 million second tranche. Conversion pricing is 80% of the lowest closing bid over five preceding trading days, with a $0.2668 floor and $2 cap.
